By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators publish new report on Autoimmune Diseases and Disorders. According to news reporting from Tehran, Iran, by NewsRx journalists, research stated, "Recently, homocysteine (Hcy), folate, and vitamin B12 have been proposed to have several roles on MS pathogenesis. We performed this study to determine the role of serum levels of Hcy, vitamin B12, and folate in patients with relapsing remitting MS (RRMS) and compared them with healthy controls."
The news correspondents obtained a quote from the research from the Tehran University of Medical Sciences, "We recruited 75 RRMS patients and 75 subjects as controls with the same age and sex. Homocysteine was measured using fluorimetric high-performance liquid chromatography. Plasma folate and vitamin B12 levels were measured through ion-capture method. Mean plasma levels of vitamin B12, folate, and Hcy in cases were 342.64 ?? 210.66 pg/ml, 9.74 ?? 4.77 ng/ml, and 22.73 ?? 11.63 ?M/L, respectively, which showed significant difference in comparison with the controls. In addition, there were significant correlations between mean serum Hcy levels and duration of disease (r=0.2, p=0.05) and treatment with interferon (r=0.21, p=0.01). In cases, Hcy level was higher among those on ? interferon (24.56 ?? 11.87 vs. 19.71 ?? 10.75, p=0.01). We concluded that serum levels of vitamin B12 and folate decreased in RRMS patients, but Hcy levels increased significantly. It seems necessary to conduct prospective trials to determine whether the treatment with supplements and correct biomarker levels in the early stage of the disease can change the course of the disease."
According to the news reporters, the research concluded: "We recommend regular checking of the serum level of Hcy in patients who use disease-modifying drugs."
For more information on this research see: Homocysteine, vitamin B12 and folate levels in Iranian patients with Multiple Sclerosis: a case control study. Clinical Neurology and Neurosurgery, 2013;115(9):1802-5. (Elsevier - www.elsevier.com; Clinical Neurology and Neurosurgery - www.elsevier.com/wps/product/cws_home/523832)
Our news journalists report that additional information may be obtained by contacting M. Moghaddasi, Dept. of Neurology, Rasool Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran. Additional authors for this research include M. Mamarabadi, N. Mohebi, H. Razjouyan and M. Aghaei (see also Autoimmune Diseases and Disorders).
Keywords for this news article include: Iran, Asia, Tehran, Neurology, Treatment, Homocysteine, Neuroimmunology, Multiple Sclerosis, Sulfur Amino Acids, Demyelinating Diseases, Immune System Diseases, Autoimmune Diseases and Disorders, CNS Demyelinating Autoimmune Diseases, Autoimmune Diseases of the Nervous System.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.